Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHSCT with Reduced-Intensity BEAM in MS
NCT03113162Phase 1Unknown
- Sponsor
- Makati Medical Center
- Start
- May 2015
- Primary completion
- May 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous hematopoietic stem cells in multiple sclerosis (MS), sponsored by Makati Medical Center. Primary endpoint: Adverse Events at 12 months. Status: unknown.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03113162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113162.